Abstract: The invention relates to a method for determining at least one characteristic parameter of a CRP specimen (3, 4), in particular a specimen of prepreg material, for aerospace, comprising the following method steps: presenting the specimen (3, 4), irradiating the. specimen (3, 4) with a predetermined spectrum of electromagnetic radiation, recording the interaction between the specimen (3, 4) and the electromagnetic radiation in a data record (20) and determining the at least one characteristic parameter from the recorded data record (20).

Abstract: The present invention provides a device, in particular within the aeronautical and aerospace fields, comprising a first and second tool and guide means, which guide the first and second tools in such a way that they press a preliminary fabric arranged in a pressing zone of the device along a second axis as said fabric moves along a first axis through the pressing zone, said second axis being substantially transverse to the first axis, so as to form a consolidated preliminary fabric, the guide means guiding the first and second tools parallel to one another, in part, along the first axis in the pressing zone.

Abstract: The present invention relates to a production method for a workpiece (15) composed of a fibre-composite material, having the following steps: at least one support means (3) is provided. A main material (6) composed of a pre-impregnated fibre semi-finished product and/or of a secondary material (7) are/is applied to the at least one support means (3) in order to form at least two blank-mould areas (1, 10), in such a manner that at least one of the at least two blank-mould areas (1, 10) has the main material, and at least one of the blank-mould areas (1, 10) has the secondary material. The blank-mould areas (1, 10) are pressure-bonded to one another to form a workpiece blank (14) such that the at least one support means (3) is provided on a surface of the workpiece blank (14). The at least one support means (3) and the secondary material (7) are removed from the workpiece blank (14) in order to form the workpiece (15).

Abstract: The present invention relates to a component, in particular in the field of aviation and spaceflight, having a resin matrix in which carbon nanotubes are embedded for high conductivity of the component.

Abstract: The invention relates to a method for joining precured stringers to at least one structural component of an aircraft or spacecraft. A vacuum arrangement required for the joining is produced in two parts. In a first step, each precured stringer is covered in advance by a covering vacuum film. The stringers prepared in this manner are arranged on the structural component. Vacuum film strips are subsequently arranged in each case on adjacent stringers and over an intermediate space between the adjacent stringers. With the use of a vacuum sealing means, the vacuum film strips and the covering vacuum films 8 form a continuous vacuum arrangement. The stringers are subsequently joined under pressurization to the structural component with the use of this vacuum arrangement.

Abstract: The invention relates to a method for joining precured stringers to at least one structural component of an aircraft or spacecraft. A vacuum arrangement necessary for the joining is produced in two parts. In a first step, each precured stringer is covered in advance with a covering vacuum film. The stringers prepared in this manner are arranged on the structural component. Respective vacuum film strips are subsequently arranged on adjacent stringers and over an intermediate space between the adjacent stringers. With the use of a vacuum sealing means, the vacuum film strips and the covering vacuum films 8 form a continuous vacuum arrangement. The stringers are subsequently joined under pressurization to the structural component with the use of this vacuum arrangement.

Abstract: The invention relates to a method for joining an uncured stringer to a structural component of an aircraft or spacecraft. The uncured stringer is supplied with at least one joining section and at least one web section. A rapidly curing low-temperature auxiliary material is deposited on web flanks of the at least one web section, which are to be supported. The at least one joining section of the uncured stringer is fitted to the structural component. Curing of the auxiliary material then takes place at a first curing temperature in order to form cured supporting elements for the web flanks of the at least one web section, which are to be supported. Curing of the uncured stringer is undertaken at a second curing temperature which is greater than the first precuring/curing temperature, and then the deposited and cured auxiliary material is removed.

Abstract: The present invention relates, in general, to CD6 and, in particular, to a CD6 ligand present on the surface of thymic epithelial cells, monocytes, activated T cells and a variety of other cell types. The invention further relates to methods of inhibiting the interaction of CD6 and the CD6 ligand, and to methods of screening compounds for their ability to inhibit that interaction. The invention also relates to antibodies, and binding fragments thereof, specific for CD6 ligand.

Abstract: The present invention relates to an isolated nucleic acid molecule having a sequence that encodes a CD6 ligand present on the surface of thymic epithelial cells, monocytes, activated T cells and a variety of other cell types. The invention further relates to a construct containing the nucleic acid molecule and to a host cell comprising same. Further, the invention relates to a method of producing a CD6 ligand.

Abstract: The present invention provides internalizing ligands (i.e., BR110 ligands) which specifically recognize and bind the BR110 antigen. After binding the antigen, the ligand and antigen form a complex. As a complex, the antigen can be detected using well known and developed methods and commercial systems.

Abstract: Novel compositions comprising Oncostatin M and congeners thereof, as well as methods for their preparation and methods for their use are provided. The compositions may be prepared by isolation from natural sources, or by recombinant means in either prokaryotic or eukaryotic host cells. In addition, the DNA and polypeptide sequences for Oncostatin M are disclosed. The compositions find use in modulating growth of cells, in particular inhibition of tumor cell proliferation, and stimulation of normal cell growth, especially cells involved in hematopoiesis. Cell growth inhibition compositions may additionally include an adjunctive agent comprising at least one of a transforming growth factor, tumor necrosis factor, or an interferon. Receptors having high affinity for Oncostatin M may additionally be used to screen polypeptides for Oncostatin M-like activity. Methods for use of antibodies to the compositions and probes specific for Oncostatin M mRNA as a means for detecting tumor cells are also provided.

Abstract: The present invention discloses a new ribosome-inactivating protein, bryodin 2, isolated from the plant Bryonia dioica. This ribosome-inactivating protein (RIP) is a type IRIP having a single polypeptide chain and no cellular receptor domain. Like many type I RIPs, bryodin 2 has a molecular weight of about 27,000 daltons and a pI of 9.5. Bryodin 2 differs from previously identified ribosome-inactivating protein in its amino acid composition, amino acid sequence, and toxicity in vitro and in vivo. Bryodin 2 is useful, as are other type I ribosome-inactivating proteins, as an abortifacient, immunomodulator, anti-tumor or anti-viral agent. Compositions comprising bryodin 2 as an immunoconjugate or fusion molecule are particularly useful to kill cells of a target population.

Abstract: Thermally stable cytosine deaminase (CDase), and the gene coding therefor, is disclosed as well as methods of isolating, purifying, and recombinantly producing the same. The thermally stable CDase can be isolated from Saccharomyces cerevisiae. The yeast isolated enzyme has a molecular weight of approximately 32 kDa, as determined by gel filtration chromatography, and is composed of two subunits, each with a molecular weight of about 17 kDa. Thermally stable yeast CDase so purified shows no significant sequence homology with other known sequenced proteins.

Abstract: Novel compositions comprising Oncostatin M and congeners thereof, as well as methods for their preparation and methods for their use are provided. The compositions may be prepared by isolation from natural sources, or by recombinant means in either prokaryotic or eukaryotic host cells. In addition, the DNA and polypeptide sequences for Oncostatin M are disclosed. The compositions find use in modulating growth of cells, in particular inhibition of tumor cell proliferation, and stimulation of normal cell growth, especially cells involved in hematopoiesis. Cell growth inhibition compositions may additionally include an adjunctive agent comprising at least one of a transforming growth factor, tumor necrosis factor, or an interferon. Receptors having high affinity for Oncostatin M may additionally be used to screen polypeptides for Oncostatin M-like activity. Methods for use of antibodies to the compositions and probes specific for Oncostatin M mRNA as a means for detecting tumor cells are also provided.

Abstract: Novel compositions comprising Oncostatin M and congeners thereof, as well as methods for their preparation and methods for their use are provided. The compositions may be prepared by isolation from natural sources, or by recombinant means in either prokaryotic or eukaryotic host cells. In addition, the DNA and polypeptide sequences for Oncostatin M are disclosed. The compositions find use in modulating growth of cells, in particular inhibition of tumor cell proliferation, and stimulation of normal cell growth, especially cells involved in hematopoiesis. Cell growth inhibition compositions may additionally include an adjunctive agent comprising at least one of a transforming growth factor, tumor necrosis factor, or an interferon. Receptors having high affinity for Oncostatin M may additionally be used to screen polypeptides for Oncostatin M-like activity. Methods for use of antibodies to the compositions and probes specific for Oncostatin M mRNA as a means for detecting tumor cells are also provided.

Abstract: The present invention is concerned with novel monoclonal antibody L53 which binds strongly to a glycoprotein antigen associated with human tumors, including carcinomas of the colon, breast, and lung, as well as melanomas. The antibody binds to normal human cells to a much lesser degree than to tumor cells. The antibody finds use in diagnostic methods for as the detection of malignant cells associated with tumors. Also disclosed is a novel 70,000-75,000 dalton glycoprotein antigen recognized by MAb L53. The L53 antigen is found on the cell surface of human tumor cells. The amino terminal amino acid sequence of this antigen is: ##STR1## in which X represents an unidentified amino acid.

Abstract: Thermally stable cytosine deaminase (CDase), and the gene coding therefor, is disclosed as well as methods of isolating, purifying, and recombinantly producing the same. The thermally stable CDase can be isolated from Saccharomyces cerevisiae. The yeast isolated enzyme has a molecular weight of approximately 32 kDa, as determined by gel filtration chromatography, and is composed of two subunits, each with a molecular weight of about 17 kDa. Thermally stable yeast CDase so purified shows no significant sequence homology with other known sequenced proteins.

Abstract: The present invention is concerned with novel monoclonal antibodies which bind strongly to a protein antigen associated with human non-small cell lung carcinomas ("NSCLC") human small cell lung carcinomas and certain other human carcinomas including many carcinomas of the colon and breast. The antibodies bind to normal human cells to a much lesser degree than to tumor cells. The antibodies find use both in diagnostic methods such as the detection of malignant cells associated with NSCLC and in therapeutic methods for treatment of human in NSCLC and certain other human carcinomas. Also disclosed is a novel 110,000 dalton glycoprotein antigen found on the cell surface of human non-small lung carcinoma tumor cells and on cells from certain other human cancers. The amino terminal amino acid sequence of this antigen is: ##STR1## in which X represents an unidentified amino acid.

Abstract: The present invention is concerned with a novel monoclonal antibody which binds strongly to a protein antigen associated with human tumors, including carcinomas of the colon and lung. The antibody binds to normal human cells to a much lesser degree than to tumor cells. The antibody finds use both in diagnostic methods such as the detection of malignant cells associated with tumors and in therapeutic methods for treatment of humans with tumors. Also disclosed is a novel 66,000 dalton glycoprotein antigen found on the cell surface of human tumor cells. The amino terminal amino acid sequence of this antigen is: ##STR1## in which X represents an unidentified amino acid.

Abstract: The present invention is concerned with a novel monoclonal antibody which binds strongly to a protein antigen associated with human tumors, including carcinomas of the colon, breast, ovary and lung, as well as melanomas and sarcomas. The antibody binds to normal human cells to a much lesser degree than to tumor cells. The antibody finds use both in diagnostic methods such as the detection of malignant cells associated with tumors and in therapeutic methods for treatment of humans with tumors. Also disclosed is a novel 100,000 dalton glycoprotein antigen found on the cell surface of human tumor cells. The amino terminal amino acid sequence of this antigen is: ##STR1## in which X represents an unidentified amino acid.